Mehra Golshan

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

William M. Sikov, Donald A. Berry, Charles M. Perou et al. · Journal of Clinical Oncology · 2014 · 1K citations · Full text

Medicine, Oncology, Pharmacology +17

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

Sibylle Loibl, Joyce O’Shaughnessy, Michael Untch et al. · The Lancet Oncology · 2018 · 771 citations

Medicine, Oncology, Pharmacology +14

Growing Use of Contralateral Prophylactic Mastectomy Despite no Improvement in Long-term Survival for Invasive Breast Cancer

Stephanie M. Wong, Rachel A. Freedman, Yasuaki Sagara et al. · Annals of Surgery · 2016 · 301 citations

Medicine, Oncology, Surgery +13

Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients

Sara M. Tolaney, Yves Boucher, Dan G. Duda et al. · Proceedings of the National Academy of Sciences · 2015 · 256 citations · Full text

Medicine, Oncology, Pharmacology +17

Application of desorption electrospray ionization mass spectrometry imaging in breast cancer margin analysis

David Calligaris, Diana Caragacianu, Xiaohui Liu et al. · Proceedings of the National Academy of Sciences · 2014 · 245 citations · Full text

Medicine, Oncology, Radiology +17